Hepatic alveolar echinococcosis: correlation between computed tomography morphology and inflammatory activity in positron emission tomography.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 07 2020
16 07 2020
Historique:
received:
05
07
2019
accepted:
18
06
2020
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
22
12
2020
Statut:
epublish
Résumé
Positron emission tomography-computed tomography (PET-CT) with 18F-fluorodesoxyglucose (FDG) is the imaging modality of choice for assessing inflammation surrounding hepatic alveolar echinococcosis (AE) lesions. This study is the first to evaluate FDG uptake in hepatic AE (n = 51) based on the standardized uptake value (SUV) and to correlate the SUVs with primary morphology and calcification patterns, based on the Echinococcus multilocularis Ulm Classification for Computed-Tomography (EMUC-CT). Our results show that the SUVs were increased for lesions with EMUC-CT types I-IV primary morphology, compared to the surrounding healthy liver tissue (SUV = 2.5 ± 0.4; p < 0.05). Type IV lesions included, by far, the highest number of PET-negative lesions. A comparison of lesions with different primary morphologies showed clear differences. The highest SUVs were found for types I and III, and the lowest was found for type IV. Type IV lesions (SUV, 3.8 ± 1.5) showed significantly lower uptake compared to type I (SUV, 6.9 ± 3.5; p = 0.030) and type III (SUV, 7.4 ± 3.9; p = 0.031) lesions. For type II lesions, the results showed only a statistical trend (SUV, 6.1 ± 3.1; p = 0.073). Due to the small number of cases, an evaluation of type V (n = 1) lesions was not possible. The different SUVs of lesions with different primary morphologies, particularly the lower FDG uptake observed in type IV lesions, suggested that these SUVs might reflect different stages of the disease.
Identifiants
pubmed: 32678174
doi: 10.1038/s41598-020-68624-9
pii: 10.1038/s41598-020-68624-9
pmc: PMC7366930
doi:
Substances chimiques
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
11808Références
Baumann, S. et al. Worldwide literature on epidemiology of human alveolar echinococcosis: a systematic review of research published in the twenty-first century, Infection. 47, 703–727 (2019).
pubmed: 31147846
Moro, P. & Schantz, P. M. Echinococcosis: a review. Int. J. Infect. Dis. 13, 125–133 (2009).
pubmed: 18938096
Romig, T. et al. An epidemiologic survey of human alveolar echinococcosis in southwestern Germany. Römerstein Study Group. Am. J. Trop. Med. Hyg. 61, 566–573 (1999).
pubmed: 10548290
Torgerson, P. R., Keller, K., Magnotta, M. & Ragland, N. The global burden of alveolar echinococcosis. PLoS. Negl. Trop. Dis. 4, e722 (2010).
pubmed: 20582310
pmcid: 2889826
Deplazes, P. et al. Global distribution of alveolar and cystic echinococcosis. Adv. Parasitol. 95, 315–493 (2017).
pubmed: 28131365
Craig, P. S. et al. A large focus of alveolar echinococcosis in central China. Lancet 340, 826–831 (1992).
pubmed: 1357252
Craig, P. S. Echinococcus multilocularis. Curr. Opin. Infect. Dis. 16, 437–444 (2003).
pubmed: 14501996
Zhang, W. et al. Epidemiology and control of echinococcosis in central Asia, with particular reference to the People’s Republic of China. Acta. Trop. 141, 235–243 (2015).
pubmed: 24686096
Craig, P. S. Epidemiology of human alveolar echinococcosis in China. Parasitol. Int. 55, 221–225 (2006).
Tiaoying, L. et al. Echinococcosis in Tibetan populations, western Sichuan Province, China. Emerg. Infect. Dis. 11, 1866–1873 (2005).
pubmed: 16485472
pmcid: 3367622
Graeter, T. et al. Proposal of a computed tomography classification for hepatic alveolar echinococcosis. World J. Gastroenterol. 22, 3621–3631 (2016).
pubmed: 27053854
pmcid: 4814648
Ammann, R. W. & Eckert, J. Cestodes. Echinococcus. Gastroenterol. Clin. North. Am. 25, 655–689 (1996).
pubmed: 8863045
Eckert, J. & Deplazes, P. Biological, epidemiological, and clinical aspects of echinococcosis, a zoonosis of increasing concern. Clin. Microbiol. Rev. 17, 107–135 (2004).
pubmed: 14726458
pmcid: 321468
Eckert, J., Gemmell, M. A., Meslin, F. X. & Pawlowski, Z. S. WHO-OIE Manual on Echinococcosis in Humans and Animals: A Public Health Problem of Global Concern (World Organisation for Animal Health, Paris, 2001).
Stojkovic, M., Mickan, C., Weber, T. F. & Junghanss, T. Pitfalls in diagnosis and treatment of alveolar echinococcosis: a sentinel case series. BMJ Open Gastroenterol. 2, e000036 (2015).
pubmed: 26462284
pmcid: 4599161
Kern, P. Clinical features and treatment of alveolar echinococcosis. Curr. Opin. Infect. Dis. 23, 505–512 (2010).
pubmed: 20683265
Torgerson, P. R. et al. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J. Hepatol. 49, 72–77 (2008).
pubmed: 18485517
Reuter, S. et al. Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin. Infect. Dis. 29, 1157–1163 (1999).
pubmed: 10524957
Reuter, S. et al. Structured treatment interruption in patients with alveolar echinococcosis. Hepatology 39, 509–517 (2004).
pubmed: 14768005
Reuter, S. et al. Long-term follow-up of metabolic activity in human alveolar echinococcosis using FDG-PET. Nuklearmedizin. 47, 147–152 (2008).
pubmed: 18690373
Stumpe, K. D. et al. F-18-fluorodeoxyglucose (FDG) positron-emission tomography of Echinococcus multilocularis liver lesions: prospective evaluation of its value for diagnosis and follow-up during benzimidazole therapy. Infection 35, 11–18 (2007).
pubmed: 17297583
Ammann, R. W. et al. Outcome after discontinuing long-term benzimidazole treatment in 11 patients with non-resectable alveolar echinococcosis with negative FDG-PET/CT and anti-EmII/3-10 serology. PLoS Negl. Trop. Dis. 9, e0003964 (2015).
pubmed: 26389799
pmcid: 4577091
Reuter, S. et al. Alveolar liver echinococcosis: a comparative study of three imaging techniques. Infection 29, 119–125 (2001).
pubmed: 11440381
Coşkun, A. et al. Alveolar echinococcosis of the liver: correlative color Doppler US, CT, and MRI study. Acta Radiol. 45, 492–498 (2004).
pubmed: 15515508
Ehrhardt, A. R. et al. Assessment of disease activity in alveolar echinococcosis: a comparison of contrast enhanced ultrasound, three-phase helical CT and [(18)F] fluorodeoxyglucose positron emission tomography. Abdom. Imaging. 32, 730–736 (2007).
pubmed: 17285403
Kaltenbach, T. E. et al. Determination of vitality of liver lesions by alveolar echinococcosis. Comparison of parametric contrast enhanced ultrasound (SonoVue®) with quantified 18F-FDG-PET CT. Nuklearmedizin. 54, 43–49 (2015).
pubmed: 25423884
Li, H. et al. Efficiency of liposomal albendazole for the treatment of the patients with complex alveolar echinococcosis: a comparative analysis of CEUS, CT, and PET/CT. Parasitol. Res. 114, 4175–4180 (2015).
pubmed: 26239800
Azizi, A. et al. Alveolar echinococcosis: correlation between hepatic MRI findings and FDG-PET/CT metabolic activity. Abdom. Imaging. 40, 56–63 (2015).
pubmed: 24970734
Zheng, J., Wang, J., Zhao, J. & Meng, X. Diffusion-weighted MRI for the initial viability evaluation of parasites in hepatic alveolar echinococcosis: comparison with positron emission tomography. Korean J. Radiol. 19, 40–46 (2018).
pubmed: 29353998
pmcid: 5768505
Li, J., Dong, J., Yang, L., Li, X. & Song, T. Comparison of [
pubmed: 30077410
Schwarze, V. et al. The use of contrast-enhanced ultrasound (CEUS) for the diagnostic evaluation of hepatic echinococcosis. Clin. Hemorheol. Microcirc. 70, 449–455 (2018).
pubmed: 30347607
Ammann, R. W., Fleiner-Hoffmann, A., Grimm, F. & Eckert, J. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J. Hepatol. 29, 994–998 (1998).
pubmed: 9875648
Kodama, Y. et al. Alveolar echinococcosis: MR findings in the liver. Radiology 228, 172–177 (2003).
pubmed: 12750459
Kratzer, W. et al. Proposal of an ultrasonographic classification for hepatic alveolar echinococcosis: Echinococcus multilocularis Ulm classification-ultrasound. World J. Gastroenterol. 21, 12392–12402 (2015).
pubmed: 26604646
pmcid: 4649122
Brunetti, E., Kern, P. & Vuitton, D. A. Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop. 114, 1–16 (2010).
pubmed: 19931502
Bresson-Hadni, S. et al. Imaging aspects and non-surgical interventional treatment in human alveolar echinococcosis. Parasitol. Int. 55(Suppl), S267-272 (2006).
pubmed: 16403670
Grimm, J., et al. Combined analysis of computed tomography and histology leads to an evolutionary concept of Echinococcus multilocularis infections in humans. PLoS Negl Trop Dis. (submitted) (2019)
Mueller, J., Stojkovic, M., Kauczor, H. U., Junghanss, T. & Weber, T. F. Performance of magnetic resonance susceptibility-weighted imaging for detection calcifications in patients with hepatic echinococcosis. J. Comput. Assist. Tomogr. 42, 211–215 (2018).
pubmed: 29189399
Brumpt, E. et al. AE hepatic lesions: correlation between calcifications at CT and FDG-PET/CT metabolic activity. Infection 47, 955–960 (2019).
pubmed: 31165442
Gottstein, B., et al. Diagnostic and follow-up performance of serological tests for different forms/courses of alveolar echinococcosis. Food and Waterborne Parasitology. e00055 (2019).
Lötsch, F. et al. FDG-PET/MRI in alveolar echinococcosis. Int. J. Infect. Dis. 64, 67–68 (2017).
pubmed: 28935243
Büther, F. et al. Clinical evaluation of a data-driven respiratory gating algorithm for whole-body positron emission tomography with continuous bed motion. J Nucl Med https://doi.org/10.2967/jnumed.119.235770 (2020).
doi: 10.2967/jnumed.119.235770
pubmed: 32060218
Smeets, E. M. M. et al. Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patients with pancreatic ductal adenocarcinoma. EJNMMI Res. 9, 24 (2019).
pubmed: 30868318
pmcid: 6419652
Høilund-Carlsen, P. F., Edenbrandt, L. & Alavi, A. Global disease score (GDS) is the name of the game!. Eur. J. Nucl. Med. Mol. Imaging. 46, 1768–1772 (2019).
pubmed: 31183636
pmcid: 6647113
Saboury, B., Salavati, A., Werner, T. & Alavi, A. Integrative imaging biomarker: Global disease assessment with PET/CT, a combination of functional and structural image quantification. J. Nucl. Med. 54, 1237 (2013).
Marin-Oyaga, V. A. et al. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature. Hell J. Nucl. Med. 18, 11–18 (2015).
pubmed: 25679073
Lee, S. J. et al. Development and validation of an 18 F-fluorodeoxyglucose-positron emission tomography with computed tomography-based tool for the evaluation of joint counts and disease activity in patients with rheumatoid arthritis. Arthritis Rheumatol. 71, 1232–1240 (2019).
pubmed: 30771237
Raynor, WY., et al. The necessity of global disease assessment in optimal management of patients with cancer. Elsevier Health Sciences. Part II, 140–145 (2018). In Alavi, A., Salavati, A., Gholamrezanezhad, A., Guermazi, A. (eds) PET-CT-MRI Applications in Musculoskeletal Disorders, Part II, An Issue of PET Clinics.